NSCLC, Stage I Clinical Trials

5 recruiting

NSCLC, Stage I Trials at a Glance

7 actively recruiting trials for nsclc, stage i are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Commack, Middletown, and Basking Ridge. Lead sponsors running nsclc, stage i studies include Guangdong Provincial People's Hospital, Memorial Sloan Kettering Cancer Center, and Greg Durm, MD.

Browse nsclc, stage i trials by phase

Treatments under study

About NSCLC, Stage I Clinical Trials

Looking for clinical trials for NSCLC, Stage I? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NSCLC, Stage I trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NSCLC, Stage I clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Phase 2

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

NSCLC, Stage I
Greg Durm, MD244 enrolled13 locationsNCT04317534
Recruiting
Phase 2

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

NSCLCNSCLC Stage IINSCLC, Stage I
Memorial Sloan Kettering Cancer Center25 enrolled7 locationsNCT07323732
Recruiting
Phase 2

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC

NSCLC Stage IINSCLC, Stage IIIANSCLC Stage IIIB
University Hospital Heidelberg20 enrolled1 locationNCT04865250
Recruiting
Phase 2

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

NSCLC Stage IINSCLC, Stage IIIANSCLC, Stage I
University Hospital, Essen90 enrolled4 locationsNCT04205552
Recruiting
Not Applicable

Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection

NSCLC, Stage IPulmonary Function AssessmentDisease Free Survival
Guangdong Provincial People's Hospital3,000 enrolled1 locationNCT06404164
Recruiting
Phase 2

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I
Tianjin Medical University Cancer Institute and Hospital65 enrolled1 locationNCT05686434